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Background: miR-139-5p was identified to be significantly down-regulated in colon tumor tissues by miRNA array.
We aimed to clarify its biological function, molecular mechanisms and direct target gene in colorectal cancer (CRC).
Methods: The biological function of miR-139-5p was examined by cell growth, cell cycle and apoptosis analysis
in vitro and in vivo. miR-139-5p target gene and signaling pathway was identified by luciferase activity assay and
western blot.
Results: miR-139-5p was significantly down-regulated in primary tumor tissues (P < 0.0001). Ectopic expression of
miR-139-5p in colon cancer cell lines significantly suppressed cell growth as evidenced by cell viability assay
(P < 0.001) and colony formation assay (P < 0.01) and in xenograft tumor growth in nude mice (P < 0.01). miR-139-5p
induced apoptosis (P < 0.01), concomitantly with up-regulation of key apoptosis genes including cleaved caspase-8,
caspase-3, caspase-7 and PARP. miR-139-5p also caused cell cycle arrest in G0/G1 phase (P < 0.01), with upregulation
of key G0/G1 phase regulators p21Cip1/Waf1 and p27Kip1. Moreover, miR-139-5p inhibited cellular migration (P < 0.001)
and invasiveness (P < 0.001) through the inhibition of matrix metalloproteinases (MMP)7 and MMP9. Oncogene
NOTCH1 was revealed to be a putative target of miR-139-5p, which was inversely correlated with miR-139-5p
expression (r = −0.3862, P = 0.0002).
Conclusions: miR-139-5p plays a pivotal role in colon cancer through inhibiting cell proliferation, metastasis, and
promoting apoptosis and cell cycle arrest by targeting oncogenic NOTCH1.
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Colorectal cancer (CRC) is the third most common
malignancy worldwide and the second leading cause of
tumor-related death in Western countries [1]. According
to International Agency for Research on Cancer, appro-
ximately 1.24 million new cases of CRC were reported
worldwide in 2008 [1]. CRC incidence rates are rapidly* Correspondence: junyu@cuhk.edu.hk; zzr-doctor@163.com
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unless otherwise stated.rising in Asian countries [2], which were formerly consid-
ered as low-risk area. So there is a growing need for
underling the molecular pathogenesis of CRC. Over the
last decade, microRNAs (miRNAs) have emerged as key
players in carcinogenesis. Aberrant expression of miRNAs
has been demonstrated to play a critical role in the initi-
ation and progression of several human cancers through
post-transcriptional regulation of gene expression [3-5].
It has been shown that miRNAs play an important
role in the development of CRC. miRNAs in CRC ex-
hibit oncogenic or tumor suppressive role by directly
regulating oncogenes or tumor-suppressor genes [6,7].
Our previous work on miRNA microarray analysis
revealed that miR-139-5p was downregulated in colon
cancers (0.10 ~ 0.15-fold of the non-tumor miR-139-5p)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of miR-139-5p in CRC remain largely unclear. In this
study, we aimed to determine its biological function,
molecular basis and target gene in CRC.
Results
miR-139-5p is frequently downregulated in primary CRC
and colon cancer cell lines
We previously performed miRNA arrays based on five
CRC patients and two advanced adenoma patients [8,9].
The miRNA array results showed that miR-139-5p was
significantly down-regulated in both CRC and advanced
adenoma compared with their adjacent normal tissues.
The Sanger database shows that miR-139-5p shares the
same precursor with miR-139-3p. However, miR-139-3p
was undetectable in CRC and the adjacent non-tumor
tissues. Therefore, our study focused on the miR-139-5p.
The downregulation of miR-139-5p in CRC was further
verified in two independent cohorts of colon cancer pa-
tients (cohort 1, n = 45; and cohort 2, n = 50, Additional
file 1: Table S1) and 7 colon cancer cell lines. Consistent
with the findings from miRNA array, there was a signi-
ficant decrease in the expression level of miR-139-5p inFigure 1 miR-139-5p was down-regulated in primary colorectal cance
primary colorectal tumors compared with their adjacent normal tissues (A1
miR-139-5p in seven colon cancer cell lines and normal colorectal tissues (nboth cohorts of CRC tumors when compared with their
matched non-tumorous tissues (P < 0.0001 in both
cohorts) (Figure 1A). We had performed qRT-PCR to
determine the level of miR-139-5p. Among the paired
samples, 89% (40/45) of cohort 1 and 98% (49/50) of
cohort 2 CRC samples showed lower miR-139-5p levels
than in the adjacent normal tissue. In addition, we exam-
ined miR-139-5p expression levels in seven colon cancer
cell lines (Caco2, DLD1, HCT116, HT29, LoVo, LS180 and
SW620). We observed that miR-139-5p was downregulated
in all seven colon cancer cell lines relative to nine normal
colon tissues (P < 0.0001) (Figure 1B). Moreover, miR-
139-5p expressions were restored in 5 CRC cell lines upon
administration of DNA methylation inhibitor 5-aza-2’-
deoxycytidine (Additional file 2: Figure S1A), which sug-
gests that epigenetic silencing may at least contributed to
the down-regulation of miR-139-5p. The correlation of
miR-139-5p expression with clinicopathological features
of 44 CRC patients was investigated. Based on univariate
analysis of this cohort, miR-139-5p was not associated
with clinicopathological features including gender, TNM
stage, tumor size and recurrence. Kaplan-Meier survival
analysis showed that miR-139-5p expression level was notr tissues and colon cancer cell lines. (A) Levels of miR-139-5p in
, Cohort 1, n = 45; A2, Cohort 2, n = 50). (B) The expression level of
= 9) by qRT-PCR.
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CRC patients (Additional file 3: Table S2 and Additional
file 4: Figure S2).
miR-139-5p suppresses colon cancer cell growth in vitro
and in vivo
The frequent downregulation of miR-139-5p in both
primary CRC tumor tissues and colon cancer cell lines
indicates that miR-139-5p might play a role in CRC
tumorigenesis. To explore the potential tumor suppres-
sive effect of miR-139-5p, miR-139-5p precursor (pre-
miR-139) was transfected into colon cancer cell lines
(DLD1, HCT116 and SW1116). We performed real-time
PCR to check the expression level of miR-139-5p and miR-
139-3p after transfected with pre-miR-139 mimics. We
observed an increase of miR-139-5p post-transfection,
while miR-139-3p showed no significantly changesFigure 2 miR-139-5p inhibited colon cancer cell growth in vitro and in
DLD1 and HCT116 were evidence by qRT-PCR after transfection of pre-miR
viability. Cell growth rates were detected by MTS assay. (C) miR-139-5p inh
analysis of DLD1 and HCT116 colony numbers (n = 3, mean ± SD) (right pa
growth curve of pre-miR-139-5p and control transfected HCT116 cells in n
tumors induced by pre-miR-139-5p or control were shown (right panel).(Additional file 2: Figure S1B). Our results demon-
strated that pre-miR-139 mimic conferred to up-
regulation of miR-139-5p, but not miR-139-3p. Ectopic
expression of miR-139-5p in DLD1 and HCT116 cells
caused a significant decrease in cell viability (P < 0.0001 in
both cell lines) (Figure 2A and B). The inhibitory effect of
miR-139-5p on cancer cell growth was further confirmed
by colony formation assay. The colonies formed in pre-
miR-139-transfected cells were significantly less than
in control-transfected cells in DLD1 and a borderline
statistically significant was observed in HCT116 as
compared with control (P = 0.07) (Figure 2C). To fur-
ther confirm the growth inhibitory effect of miR-139-5p
on colon cancer cells, a xenograft tumor growth assay
was performed. The subcutaneous tumor growth curve
of HCT116 stably expressed miR-139-5p or control
in vivo was shown in Figure 2D. The tumor volume wasvivo. (A) Ectopic expression of miR-139-5p in colon cancer cell lines
-139. (B) miR-139-5p significantly inhibited DLD1 and HCT116 cell
ibited DLD1 and HCT116 cells colony formation (left panel). Quantitative
nel). (D) miR-139-5p inhibited colon cancer cell growth in vivo. Tumor
ude mice. Data are mean ± SD (n = 4/group) (left panel). Images of the
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pared to the control mice (P < 0.01). These results pro-
vided further evidence that miR-139-5p plays a tumor
suppressive role in colon cancer.
miR-139-5p induces G0/G1 cell cycle arrest in colon
cancer cells by induction of p53, p21Cip1/Waf1 and p27Kip1
We investigated the effect of miR-139-5p on cell cycle
distribution. Concomitant with this inhibition of cell
proliferation, there was a significant increase in the num-
ber of cells accumulating in the G0/G1 phase in DLD1
and HCT116 (Figure 3A). p21Cip1/Waf1 and p27Kip1 are
two important cyclin-Cdk inhibitors that negatively regu-
late G1 phase progression. Therefore, we determined the
expression levels of these two cell cycle inhibitors in pre-
miR-139-transfected. Ectopic expression of miR-139-5p
induced p53 and p27Kip1 protein expression in both DLD1
and HCT116 cells (Figure 3B); however, upregulation
of p21Cip1/Waf1 was only observed in HCT116 cells
(Figure 3B). Thus, miR-139-5p suppressed cell prolifer-
ation by inducing a G0/G1 cell cycle arrest mediated
by induction of p21Cip1/Waf1 and p27Kip1.Figure 3 miR-139-5p induced colon cancer cell apoptosis and cell cyc
G0/G1 phase in DLD1 and HCT116 cells (left panel). Quantitative analysis o
repeated three times in triplicate. Data are mean ± SD. (B) G0/G1 phase ce
p53 were determined by western blot in DLD1 and HCT116 cells (C) miR-1
examined by flow cytometry analysis of Annexin V-APC and 7-AAD double
cells, respectively. (D) Apoptotic-related protein expression (PARP, caspase-miR-139-5p induces cell apoptosis by regulating
caspase-dependent apoptosis pathway
In order to determine whether the decrease in colon cell
growth by miR-139-5p was due to an induction of apop-
tosis, we evaluated the rate of cellular apoptosis using
Annexin V-APC and 7-AAD staining by flow cytometry.
As shown in Figure 3C, the number of both early and
late apoptotic cells at 48–96 h post-transfection of pre-
miR-139 in DLD1 and HCT116 cells was substantially
increased as compared to control pre-miRNA trans-
fected DLD1 and HCT116 cells. Induction of apoptosis
was further confirmed by the expression of apoptosis-
related proteins using western blot. As shown in
Figure 3D, the protein levels of the active forms of
caspase-3, caspase-7, caspase-8 were enhanced. To fur-
ther confirm their activities in active form, the cleavage
of nuclear poly (ADP-ribose) polymerase (PARP) was
determined. As expected, the level of cleaved PARP was
enhanced in the pre-miR-139-transfected cells compared
to the control cells both in DLD1 and in HCT116
(Figure 3D). These results inferred that apoptosis con-
comitant with cell cycle arrest induced by miR-139-5ple arrest at G0/G1 phase. (A) miR-139-5p caused cell cycle arrest at
f G0/G1 proportion in DLD1 and HCT116, The experiments were
ll cycle related protein expression including p21Cip1/Waf1, p27Kip1 and
39-5p induced apoptosis in DLD1 and HCT116 cells. Cell apoptosis was
-staining. Data represented the average of the early and late apoptotic
3, 7, 8) were detected by western blot.
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ition in miR-139-5p-expressing colon cancer cells.
miR-139-5p suppresses CRC cell migration and
invasiveness of colon cancer cell lines
We next tested whether miR-139-5p could alter migra-
tion and invasiveness of colon cancer cells in vitro. DLD1
and SW1116 cells were transfected with pre-miR-139 or
control induction of miR-139-5p significantly decreased
the migrated cells in DLD1 (P < 0.001) and in SW1116
(P < 0.001) compared to control cells (Figure 4A). More-
over, miR-139-5p markedly slowed cell migration scratchy
“wound” at edges of SW1116 and HCT116 cells
(Figure 4B and Additional file 5: Figure S3). The reduc-
tion in wound closure by miR-139-5p further confirmed
its effect in suppressing cell migration.
To study the effect of miR-139-5p on the invasiveness
of colon cancer, DLD1 and SW1116 cells were trans-
fected with pre-miR-139 or Control miRNA using a
Matrigel model (Figure 4C). In vitro invasively growing
colon cancer cells were significantly impaired in DLD1
(P < 0.01) and in SW1116 (P < 0.01) when transfected
with pre-miR-139 (Figure 4C).
The matrix metalloproteinases (MMPs) are family mem-
bers of extracellular proteinases that regulate basic cellular
processes including survival, migration and morpho-
genesis and degradation extracellular matrix during the
cancer metastatic process [10,11]. Among the MMPs
members, MMP7 and MMP9 cleave the extracellular
domain of NOTCH1 and activate NOTCH1 downstream
target gene expression [12,13]. Therefore, we examinedFigure 4 miR-139-5p inhibited colon cancer cell migration and invasio
significantly inhibited cell migration ability as determined by cell migration
SW1116. The data are means ± SD. (B) The inhibition on cell migration by miR-1
of miR-139-5p in DLD1 and SW1116 cells significantly suppressed cell inva
significantly downregulated MMP7 and MMP9 protein levels in both colonthe expression levels of these two proteinases and
found that ectopic expression of miR-139-5p markedly
suppressed protein expression of MMP7 and MMP9
(Figure 4D), concomitant with the inhibition of cell
migration and invasion.
miR-139-5p targets NOTCH1 via binding to its 3’UTR
We searched for the direct target of miR-139-5p based
on the following criteria: the target should have on-
cogenic property and regulate the cell migration and
invasion. Among the top 100 targets of miR-139-5p
predicted by 2 bioinformatics algorithms (TargetScan
and miRanda), NOTCH1 fit our criteria. The 3' un-
translated region (3'UTR) of NOTCH1 contains a con-
served binding site for miR-139-5p (Figure 5A). To test
the specific regulation through the predicted binding
sites, we constructed a reporter vector which consists
of the luciferase coding sequence followed by the
3’UTR of NOTCH1 (Luc-NOTCH1-3’UTR) (Figure 5B).
Wild type (Luc-NOTCH1-3’UTR) or mutated sequence
(Luc-NOTCH1-mut 3’UTR) within the putative binding
sites was cloned into the pMIR-REPORT vector (Figure 5A
and B). Co-transfection experiments in HCT116 cells
showed that miR-139-5p significantly decreased the lu-
ciferase activity of Luc-NOTCH1-3’UTR (P < 0.05), but
this was not observed in Luc-NOTCH1-mut 3’UTR
(Figure 5C). Our data thus demonstrated that NOTCH1
was a direct target of miR-139-5p.
To further confirm that miR-139-5p targets NOTCH1,
pre-miR-139 or control was transfected into DLD1 and
HCT116 cells. Transfection of pre-miR-139 resulted inn. (A) Re-expression of miR-139-5p in DLD1 and SW1116 cells
assay (left panel) Quantitative analysis of migrated cell in DLD1 and
39-5p was further confirmed by wound-healing assay. (C) Re-expression
sive ability as determined by cell invasion assay. (D) miR-139-5p
cancer cell lines.
Figure 5 NOTCH1 is a direct target of miR-139-5p in colon cancer. (A) Human NOTCH1 3’UTR binding site for miR-139-5p. (B) The miR-139-5p
wild type binding sequence or its mutated form was inserted into C-terminal of the luciferase gene to generate pMIR-NOTCH1-3’UTR or
pMIR-NOTCH1-mut-3’UTR, respectively. (C) miR-139-5p targeted the wild-type but not the mutant 3’UTR of NOTCH1. The data are means ± SD. (D)
Ectopic expression of miR-139-5p downregulated NOTCH1 mRNA expression in DLD1 and HCT116 cells as determined by quantitative RT-PCR. (E)
miR-139-5p decreased NOTCH1 protein level in DLD1 and HCT116 by western blot. (F) miR-139-5p significantly suppressed NOTCH1 downstream
effectors including hairy and enhancer of split-1 (HES1), cyclin D1 and FADD-like apoptosis regulator (CFLAR) transcription. (G) Expression of NOTCH1 is
significantly upregulated in primary colorectal tumors compared with their adjacent normal tissues (n = 45). (H) Scatter plots showing the
inverse association between miR-139-5p level and NOTCH1 mRNA expression.
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expression by qRT-PCR (Figure 5D) and by western blot
(Figure 5E), respectively. Consistent with this finding, ec-
topic expression of miR-139-5p significantly suppressed
NOTCH1 downstream effectors, including hairy and en-
hancer of split-1 (HES1) (P < 0.001), Cyclin D1 (P < 0.001)
and FADD-like apoptosis regulator (CFLAR) (P < 0.05)
transcription (Figure 5F). Collectively, these results showed
that mir-139-5p could regulate NOTCH1 and its mediated
signal transduction.
NOTCH1 is upregulated in primary CRC tumors and
inverse correlated with miR-139-5p expression
To assess the importance of NOTCH1 in primary CRC,
we compared the level of NOTCH1 expression in 45
paired tumor and adjacent normal tissues. The expres-
sion of the NOTCH1 mRNA was significantly increased
in CRC tumors compared to the adjacent normal tissues(P < 0.0001; Figure 5G). NOTCH1 was overexpressed in
91% (41/45) of tumors compared with their normal
counterparts.
We evaluated the correlation between NOTCH1 mRNA
and miR-139-5p expression in 45 pairs of primary CRC.
Expression of NOTCH1 mRNA and miR-139-5p exhibited
a significant inverse correlation as calculated by Pearson
correlation (r = −0.3862, P = 0.0002) (Figure 5H). This result
further supported that miR-139-5p targets to NOTCH1.
We investigated the effect of NOTCH1 on cell
growth by NOTCH1 knockdown experiment. Knock-
down of NOTCH1 was evidenced by markedly decrease
of NOTCH1 protein expression (Additional file 6:
Figure S4A). Knockdown of NOTCH1 caused a significant
reduction in cell viability and an increased G0/G1 phase
in HCT116 (P < 0.0001, Additional file 6: Figure S4B
and S4C), indicating the potential oncogenic function of
NOTCH1 in colon cancer.
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miR-139-5p is down-regulated in inflammatory bowel
disease-associated neoplastic transformation, primary
CRC and the metastasis site [14-18]. Our data also indi-
cated that miR-139-5p showed a reduced expression in
advanced adenoma, suggesting the dysregulation of miR-
139-5p is an early event of colorectal tumorigenesis.
Further work on two cohorts of CRC patients evaluated
by qRT-PCR verified that miR-139-5p was indeed dra-
matically downregulated in tumor samples compared to
the adjacent normal tissues (P < 0.0001 in both cohorts)
(Figure 1). In addition to CRC, down-regulation of miR-
139-5p has been reported by miRNA profile studies on
gastric cancer [19], endometrial serous adenocarcinoma
[20] and HCC [21]. Epigenetic silencing of miRNAs with
tumor suppressor features is a common hallmark of
human tumors. Human miR-139-5p is embedded in the
intronic region of PDE2A gene on chromosome 11q13.4.
Most recently it was documented that miR-139 was
silenced with its host gene PDE2A through histone
methylation in lung cancer [22]. EZH2 was also reported
to silence miR-139-5p through H3K27 methylation in
human hepatocellular carcinoma [23]. In gastric cancer,
HER2 cooperates with CD44 and down-regulates miR-
139 via histone H3K9 deacetylation in the miR-139 pro-
moter region [24]. In colorectal cancer, we have found
that miR-139-5p expression is restored in CRC cell lines
upon administration of DNA methylation inhibitor 5-
aza-2’-deoxycytidine (Additional file 2: Figure S1A). This
suggests that epigenetics regulation could contribute
to the down-regulation of miR-139-5p. Except for the
epigenetics regulation, Schepeler and colleagues reported
that WNT pathway suppressed the expression of miR-
139-5p in CRC. Abrogation of the WNT pathway induced
the expression of miR-139-5p but not miR-139-3p in
DLD1 cell [18]. Collectively, silencing or downregulation
of miR-139-5p can be mediated by different mechanisms
in human cancer.
We therefore characterized the putative tumor sup-
pressive function of miR-139-5p in human colon cancer
cell lines. We found that the restoration of miR-139-5p
in the colon cancer cell lines DLD1 and HCT116 signifi-
cantly inhibited cell proliferation as evidenced by cell
viability and colony formation assays (Figure 2). In nude
mice, colon cancer cells over-expressing miR-139-5p dis-
played a significantly lower growth rate than the control
cancer cells (Figure 2D). Furthermore, we performed
FACS to evaluate the effects of miR-139-5p on the cell
cycle in colon cancer cells. We revealed a concomitant
increase of cells in G0/G1, which lead to inhibition of
cell proliferation (Figure 3A). Previous study suggested
that miR-139-5p did not affect the proliferation pheno-
type and DNA profile of breast cancer cell MDA-MB-
231 based on Doxycycline-induced plasmid expression[25]. However, miR-139-5p shows an anti-proliferative
effect in colorectal cancer. This discrepancy may be
attributed to a tissue specific function of miR-139-5p
signaling in CRC compared with other solid tumors.
On the basis of the immunoblot analysis of negative
cell-cycle regulators, G0/G1 arrest by miR-139-5p was
most likely associated with the induction of p53,
p21Cip1/Waf1 and p27Kip1 (Figure 3B). It is well known
that p53 acts as a putative mediator to induce cell cycle
arrest and to allow either DNA repair or apoptosis
through transcriptional upregulation of the cyclin
dependent kinase (CDK) inhibitor p21Cip1/Waf1, an
active inhibitor of CDKs [26]. p21Cip1/Waf1 is a direct
regulator of the cell cycle, inducing growth arrest in
G1-phase of the cell cycle by binding to and thus inhi-
biting the activity of cyclinD-CDK2/4 complexes [27].
Increased protein expression of p21Cip1/Waf1 prevents
cyclinD-CDK2/4 mediated phosphorylation of retino-
blastoma protein (pRb), thus, inhibiting E2F transcrip-
tional activity and cell cycle progression to S-phase
[28]. p27Kip1 is a potent inhibitor of cyclin D/CDK4
and cyclin E/CDK2 activities. The role of p27Kip1 as a
major player in G1 arrest has been well accepted [29].
In this regard, miR-139-5p mediated G1 cell cycle arrest in
colon cancer may be partly contributed by a mechanism in-
volving up-regulation of protein expression of p21Cip1/Waf1
and p27Kip1.
In the present work, we showed that, in addition to in-
hibition of cell proliferation, the growth inhibitory effect
of miR-139-5p was also related to induction of apoptosis
(Figure 3C). We observed that induction of miR-139-5p
mediated apoptosis occurs by the modulation of extrin-
sic apoptosis pathway. Apoptosis induced by extrinsic
pathways has been considered to be an important antitu-
mor mechanism [30-32]. After transfection with miR-
139-5p, the protein expression of the downstream active
apoptosis executors caspase-8, caspase-7, caspase-3 was
upregulated and enhanced level of cleaved PARP indi-
cated caspase 3 was functionally active (Figure 3D). The
extrinsic apoptosis pathway is initiated by the binding of
extracellular death ligands such as TNFα to transmem-
brane death receptors. Engagement of death receptors
with their cognate ligands provokes the recruitment of
adaptor proteins such as Fas-associated death domain
protein, which in turn recruits and aggregates several
molecules of caspase-8, thereby promoting its auto-
processing and activation [33]. Activation of caspase-8
processes other effector caspase members, including
caspase-3 and caspase-7 to initiate a caspase cascade.
These effectors further initiate the proteolytic cleavage
of the nuclear enzyme PARP, causing loss of DNA repair,
cellular disassembly and finally apoptosis.
In vitro assays showed that re-expression of miR-139-
5p inhibited the cell migration and invasive capabilities
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spreading effect and cell motility caused by miR-139-5p
in colon cancer cells was revealed to be associated with
the inhibition of the protein expression of cell migration
and invasion molecules MMP7 and MMP9 (Figure 4D).
MMP7 is an established instigator of aggressive behav-
ior in a number of cancer types including CRC [34,35].
MMP9 has been identified as a critical component for
priming of the pre-metastatic niche [36]. Thus, down-
regulation of MMP7 and MMP9 expression by miR-139-
5p contributed to dampened cell spreading and invasion
ability. In keeping with our finding, a recently published
study also suggested that a plasmid-based stable ex-
pression of miR-139-5p in HCT116 cells significantly
suppressed cell migration and invasion [17].
Having shown the crucial role of miR-139-5p in sup-
pressing CRC development, we sought for the possible
gene effectors participating in its function. Of note, a
single miRNA can regulate a multitude of target genes
concomitantly; for instance, it has been reported that
miR-139-5p suppresses progression of liver cancer by
down-regulating Rho-kinase 2 [21]; and miR-139-5p
could repress the activity of RAP1B [37] and IGF-IR [17]
in colon cancer. Among the miRNAs predicted to target
genes, we found that NOTCH1 acts as a critical effector
of miR-139-5p. We showed that miR-139-5p was able
to significantly repress the luciferase activity of Luc-
NOTCH1-3’UTR by targeting the 3’UTR of NOTCH1
mRNA (Figure 5A-C). We found that c-JUN also con-
tained evolutionarily conserved binding site for miR-139-
5p based on the in silicon search. However, miR-139-5p
showed no effect on the wild type c-JUN-3’UTR or the
mutant c-JUN-3’UTR reporter activity (Additional file 7:
Figure S5). Therefore we focused on NOTCH1 for further
analysis. We also successfully verified that downstream
targets of NOTCH1 were negatively regulated by miR-
139-5p including HES1, cyclin D1 and CFLAR (Figure 5F),
further reaffirming that miR-139-5p regulated NOTCH1
signal transduction by controlling the expression level of
NOTCH1.
NOTCH signaling pathway consists of three compo-
nents: the NOTCH ligands (JAG1, JAG2, DLL1, DLL3,
DLL4), NOTCH receptors 1–4, and downstream target
genes. Aberrantly activated NOTCH signaling has been
observed during the carcinogenesis of several human
cancers [38]. NOTCH1 which is prominently expressed by
epithelial cells of the crypts promotes tumor growth by
enhancing the G1-S transition of the cell cycle and by
increasing cell migration and invasion under pathological
conditions [39-41]. We observed that the NOTCH1
mRNA expression was inversely correlated with miR-
139-5p expression in CRC patients (r = −0.3862, P = 0.0002)
(Figure 5H), suggesting miR-139-5p potentially inhibits
NOTCH1 mRNA expression. In addition, othermiRNAs (miR-34a, miR-144) were also reported to sup-
press NOTCH1 in CRC [42,43]. Subsequent functional
validation revealed the decreased cell proliferation when
NOTCH1 was downregulated in colon cancer cells
(P < 0.0001) (Additional file 6: Figure S4B). In agreement
with our results, it has been shown that suppression of
NOTCH1 inhibits tumor growth in human HCC [44]
and in osteosarcoma [45] by regulating cell proliferation
and cycle. However, in the Kaplan-Meier survival analysis,
there is no association between miR-139-5p or NOTCH1
mRNA and patient disease-free survival and overall sur-
vival in colorectal patients of our cohort (Additional file 4:
Figure S2 and Additional file 8: Table S3).
Recent studies have reported that miR-139-5p was a
potential prognostic marker for renal cell carcinoma and
endometrial serous adenocarcinoma [46,20]. The clinical
value of miR-139-5p in CRC is still controversial. It was
reported that higher level of miR-139-5p was associated
with more aggressive disease of colorectal cancer [16],
whereas a recent study suggested that decreased miR-
139-5p was associated with CRC disease progression and
metastasis based on a cohort of 34 CRC patients [17]. In
our study, miR-139-5p was not found to be associated
with clinicopathological features including survival of
CRC patients. The clinical value of miR-139-5p needs
future investigations on larger cohorts of CRC samples.
Conclusions
In conclusion, we have identified that miR-139-5p was
frequently under-expressed in CRC. miR-139-5p inhibits
cell growth both in vitro and in vivo. The mechanisms
by which miR-139-5p acts as a tumor suppressor in
CRC involve inhibition of cell proliferation and metas-
tasis, and induction of G0/G1 arrest and apoptosis
through repression of oncogenic NOTCH1.
Methods
Tumor cell lines
Eight colon cancer cell lines (Caco2, DLD1, HCT116,
HT29, LoVo, LS180, SW620 and SW1116) were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA). Cells were cultured in DMEM (Gibco
BRL, Rockville, MD) and McCoy’s 5A modified (Invitrogen;
Life Technologies, Carlsbad, CA) medium supplemented
with 10% fetal bovine serum (FBS, HyClone, Logan, UT)
and incubated in 5% CO2 at 37°C.
Primary tumor and adjacent non-tumorous tissue samples
Two cohorts of totally 95 histologically confirmed spor-
adic CRC patients diagnosed in the Prince of Wales
Hospital (between November 1999, and January 2011)
were included in this study (Additional file 1: Table S1).
In addition, nine biopsies of normal colon mucosa from
healthy controls during colonoscopy were obtained in
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given written informed consent according to the Helsinki
declaration and the study protocol was approved by the
Clinical Research Ethics Committee of the Chinese
University of Hong Kong.Real-time quantitative PCR for miRNA expression analyses
Total RNA was extracted from cell pellets and tissue sam-
ples using miRNeasy Mini Kit (Qiagen, Hilden, Germany).
Quantitative reverse transcription (qRT)-PCR of miR-
139-5p was performed using the TaqMan miRNA reverse
transcription kit (Applied Biosystems; Life Technologies)
and the TaqMan human miRNA assay kit (assay ID:
miR-139-5p: 002289, and RNU6B: 001093) [8]. The com-
parative Ct method was used to calculate the relative
abundance of miRNA compared with RNU6B expression
(Fold difference relative to RNU6B).miRNA transfection and RNA interference
Human miR-139-5p precursor (pre-miR-139, MC11749)
and the miRNA Mimic Negative Control (control) were
purchased from Ambion (Ambion Life Technologies,
Austin, TX) and then transiently. Cell was seeded in
24-well plate at 60% confluence and transfected with
15 pmole miRNA per well using Lipofectamine 2000
(Invitrogen). siRNAs against human NOTCH1 (Santa
Cruz Biotechnology, Santa Cruz, CA) were delivered
into cell using Lipofectamine 2000. Cells transfected
with miRNA or siRNA were harvested 12 h to 48 h
post-transfection.Cell viability assay
After 24 h of transfection of miRNA/siRNA, the cells
were digested and re-seeded in 96-well plates (1.5 × 103
per well) for cell viability assay using MTS (Promega,
Madison, WI). 20 uL of reaction solution was added to
cultured cells in 100 uL culture medium and incubated at
37°C for 1.5 h. The optical density was measured at a
wavelength of 492 nm. The cell viability assay was carried
out in four wells for three independent experiments.Colony formation assay
HCT116 and DLD1 cells (5 × 104/well) were plated in
a 24-well plate and transfected with pre-miR-139 or
control RNA. After 24 h, the cells collected and seeded
(1 000–1 500/well) in a fresh 6-well plate for 10 days.
Surviving colonies (>50 cells per colony) were counted
after fixed with methanol/acetone (1:1) and stained with
5% Gentian Violet (ICM Pharma, Singapore, Singapore).
The experiment was carried out in triplicate wells for
three times.Cell cycle analysis and apoptosis assay
Cells used for cell cycle analysis were plated 24 h prior
to transfection with miRNAs in 24-well plate using Lipo-
fectamine 2000 per manufacturer's instructions. Cells
were trypsinized and then collected by centrifugation at
2,000 rpm for 6 min. Cell pellets were rinsed once with
phosphate-buffered saline (PBS) and fixed in 70% (v/v)
ice-cold ethanol for at least 16 h at −20°C. Cells were resus-
pended and stained with 50 μg/mL propidium iodide (BD
Biosciences, Erembodegem, Belgium) containing RNase A
for 30 min at 37°C in the dark. Apoptosis was determined
by dual staining with Annexin V-Allophycocyanin (APC)
and 7-Aminoactinomycin D (7-AAD) (BD Biosciences,
Erembodegem, Belgium). Briefly, cells were collected
48 h after transfected with pre-miR-139 or control, and
stained with Annexin V-APC and 7-AAD according
to the manufacturer’s instruction. The combination of
Annexin V-APC and 7-AAD staining distinguished early
apoptotic cells (Annexin V+, 7-AAD-) and late apoptotic
cells (Annexin V+, 7-AAD+). The cells were sorted by
FACS-Calibur System (BD Biosciences) and cell-cycle pro-
files and apoptosis were analyzed by ModFit 3.0 software
(BD Biosciences). The assay was carried out in triplicate
for three times.
Cell migration assays and wound healing assay
To measure cell migration, 8-mm pore size-culture inserts
(Transwell; Falcon, BD Biosciences) were placed into the
wells of 24-well culture plates, separating the upper and
the lower chambers. In the lower chamber, 600 μL DMEM
containing 10% FBS was added. Then 1 × 105/well cells
were added to the upper chamber. After 24 h incubation,
cells that had migrated through the transwell membrane
were stained with crystal violet, and counted (four high
power fields, ×100 magnification). In addition, wound
healing assay was also performed for analysis of cell migra-
tion in vitro. Briefly, cells transfected with either miR-139
mimics or and negative control miRNA were cultured in
six-well plates (5 × 105 cells per well). When the cells grew
up to 90% confluence, a single wound was made in the
center of cell monolayer using a P-200 pipette tip. The
wound closure areas were visualized under phase-contrast
microscope with a magnification × 100, and the migrated
cells were counted. The experiment was performed in
triplicate wells for three times.
Cell invasion assay
Cell invasion was performed by Matrigel invasion assay
(BD Biosciences). SW1116 and DLD1 cells transfected
with pre-miR-139 or control for 48 h were harvested,
suspended (1 × 105/well) in 500 uL serum-free medium
and then loaded onto the upper compartment of cham-
ber. The lower chamber contains 600 uL DMEM media
and 10% FBS. After 24 h incubation, cells that had
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with crystal violet, and counted (five high power fields,
×100 magnification). Three independent experiments
were conducted.
Vector construction and dual-luciferase reporter assay
The potential miR-139-5p binding sites were predicted
by TargetScan (www.targetscan.org) and miRanda (www.
microRNA.org). Sequence of 42 bp segment with the
wild-type or mutant seed region of NOTCH1 was
synthesized and cloned into pMIR-REPORT luciferase
vector (Applied Biosystems; Life Technologies). The
mutant NOTCH1 3’UTR sequence was prepared by
deleting 10 nucleotides in the seed region. The syn-
thesized oligos were shown as follows: Wild type of
NOTCH1: 5’-CTA GTG ACT TTA AAA GTG ATC
TAC ATG AGG AAC TGT AGA TGA TGT GAG CT-
3’; 5’- CAC ATC ATC TAC AGT TCC TCA TGT AGA
TCA CTT TTA AAG TCA-3’; Mutant type of
NOTCH1: 5’- CTA GTG ACT TTA AAA GTG ATC
TAC ATG AGT GAT GTG AGC T-3’; 5’- CAC ATC
ACT CAT GTA GAT CAC TTT TAA AGT CA-3’;
Cells (1 × 105/well) transiently transfected with pre-
miR-139 or control (at 30 nM final concentration)
were seeded in 24-well plates. pMIR-REPORT vector
(195 ng/well) and pRL-TK vector (5 ng/well) were
cotransfected using lipofectamine 2000 (Invitrogen). Cells
were harvested 48 hours post-transfection and luciferase
activities were analyzed by the dual-luciferase reporter
assay system (Promega, Madison, WI).
Western blot analysis
Total protein was extracted and protein concentration
was then measured by the DC protein-assay method of
Bradford (Bio-Rad, Hercules, CA). A total of 20 mg pro-
tein from each sample was used for western blotting.
The primary antibodies for caspase 3, caspase 7, caspase
8, PARP, p27 Kip1 and NOTCH1 were purchased from
Cell Signaling Technology (Danvers, MA, USA). Anti-
bodies for p53, p21Cip1/Waf1, MMP7, MMP9 and GAPDH
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Proliferating cell nuclear antigen was purchased from
Abcam. Bands were quantified by scanning densitometry.
All of the western blot data have been repeated three
times independently and only representative images were
showed in the Figures.
In vivo tumorigenicity
miR-139-5p expression plasmid pCMV-139-5p and con-
trol plasmid pCMV-Ctrl (Origene, Rockville, MD) were
delivered into cells using Lipofectamine 2000 and stable
cell lines were created from puromycin-resistant colonies.
HCT116 cells (2 × 106) stably expressing pCMV-139-5p
or HCT116 control cells (pCMV-Ctrl) were injectedsubcutaneously into the left flank of the female BALB/
c nude mice (4 weeks old), respectively (n = 4 mice per
group). Tumour size was measured every 3 day using
caliper, and the tumor volume (V) was calculated as
(l × w × w)/2, with l indicating length and w indicating
width. Mice were killed by cervical dislocation in day
28, and the tumors were excised and snap-frozen for
protein extraction. All experimental procedures were
approved by the Animal Ethics Committee of the Chinese
University of Hong Kong.Statistical analysis
Statistical analysis was carried out using SPSS 16.0 for
Windows. All measurements or variables were shown as
mean ± SD. Results of miR-139-5p level between paired
samples determined by the Wilcoxon matched pairs test.
Results of colony formation assays, flow-cytometry ana-
lyses, cell growth, migration and invasion assays were
analyzed by student T test. Repeated Measures ANOVA
was used to compare the tumor growth rate between
two groups in the in vivo assay. Based on the expression
levels in tumor, the miR-139-5p expression in CRCs was
categorized as high (miR-139-5p level in tumor > =me-
dian) and low (miR-139-5p level in tumor <median).
The Pearson's chi-squared test was used to analyse
the association of miR-139-5p expression and clinical-
pathological parameters. Kaplan-Meier tests were used
for survival analysis. Overall survival times were calcu-
lated from the date of curative surgery to death or last
follow-up of patients. A P < 0.05 was taken as statistical
significance.Additional files
Additional file 1: Table S1. Clinicopathologic Characteristics of 95
patients with colorectal cancer included in the study.
Additional file 2: Figure S1. (A) The expression level of miR-139-5p was
restored in CRC cell lines upon administration of DNA methylation inhibitor
5-aza-2’-deoxycytidine. 5AZA: 5-aza-2’-deoxycytidine. (B) Overexpression of
Pre-miR-139 increased the miR-139-5p level in HCT116, DLD1 and SW1116.
Additional file 3: Table S2. Correlation between miR-139-5p expression
and clinicopathologic parameters in 44 CRC patients (cohort 1).
Additional file 4: Figure S2. Kaplan-Meier survival curves for patients
with colorectal cancer in Cohort 1, stratified according to miR-139-5p
(A and B) or NOTCH1 (C and D) expression levels. The follow-up data for
one patient is not available, n = 44.
Additional file 5: Figure S3. Overexpression of miR-139-5p in HCT116
significantly suppressed cell migration ability as determined by
wound-healing.
Additional file 6: Figure S4. Role of NOTCH1 in colon cancer. (A)
Knock-down of NOTCH1 was evidenced by markedly decrease of
NOTCH1 protein expression in HCT116 cells by si-NOTCH1. (B) NOTCH1
knock-down significantly suppressed cell viability in HCT116 cells. (C)
si-NOTCH1 caused cell cycle arrest at G0/G1 phase in HCT116. Quantitative
analysis of DNA profile in HCT116 (right panel). The experiments were
repeated three times in triplicate. Data are mean ± SD.
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http://www.molecular-cancer.com/content/13/1/124Additional file 7: Figure S5. miR-139-5p showed no significant effect
on JUN in HCT116. (A) Human JUN 3’UTR binding site for miR-139-5p.
(B) The miR-139-5p wild type binding sequence or its mutated form was
inserted into C-terminal of the luciferase gene to generate pMIR-JUN-3’UTR or
pMIR-JUN-mut-3’UTR, respectively. (C) miR-139-5p showed no significant effect
on the wild-type or the mutant 3’UTR of JUN. The data are means ± SD.
Additional file 8: Table S3. Correlation between NOTCH1 mRNA
expression and clinicopathologic parameters in 44 CRC patients (cohort 1).
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